AKBA$1.21
$1.24
Chart
Performance
Key Stats
AI AKBA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAkebia Therapeutics presents a mixed investment profile. While its performance metrics and product pipeline show promise, current financial struggles and a challenging market environment necessitate a cautious approach. Its focus on kidney disease therapeutics offers strong thematic potential.
Thematic
Akebia Therapeutics is positioned within the growing biopharmaceutical sector, specifically targeting kidney diseases and associated conditions like anemia and iron deficiency. The increasing prevalence of chronic kidney disease (CKD) and an aging global population are significant tailwinds.
Fundamental
Akebia exhibits negative earnings and a substantial net loss, with a significant negative equity position. While revenue has shown fluctuations, the company's profitability remains a significant concern. Its debt levels have decreased, but free cash flow generation is negative.
Technical
The stock price has experienced a significant decline, trading well below its 52-week high. While some short-term indicators suggest potential oversold conditions, the longer-term trend and recent price action are largely negative. The stock is trading below key moving averages.
| Factor | Score |
|---|---|
| Kidney Disease Market Growth | 90 |
| Anemia Treatment Innovation | 85 |
| Iron Deficiency Management | 75 |
| Drug Development Pipeline | 70 |
| Regulatory Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 5 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 65 |
| Support & Resistance | 55 |
| Price Performance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Earnings Surprises
Akebia Therapeutics (AKBA) has demonstrated a pattern of positive earnings surprises, with reported EPS exceeding estimates in 4 out of the last 5 reported quarters. The most recent quarter (2025 Q2) showed a significant positive surprise of 166.67% (reported $0.03 vs. estimate -$0.04).
Strong Short-to-Medium Term Performance
The stock has shown robust performance over various periods: 57.17% over 6 months, 90.26% year-to-date (YTD), and 151.04% over the last 1 year. This indicates strong positive momentum.
Bearish Points (9)
Inconsistent EPS Performance
Despite recent positive surprises, the overall EPS trend has been volatile and largely negative. The EPS TTM is -$0.21, and annual EPS has been negative for all reported years (2021-2024). Quarterly EPS estimates are also negative for the upcoming quarters.
Negative Earnings and High P/E
The company currently has a negative trailing twelve months (TTM) EPS of -$0.21, resulting in a negative P/E ratio (reported as -25.8 in summary and not applicable in ratios). This indicates that the company is not currently profitable on a per-share basis.
Calendar
August 2025
7
Next Earnings Date
H: $-0.01
A: $-0.03
L: $-0.04
H: 50.80M
A: 47.64M
L: 45.80M
Profile
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
7.40 USD
The 39 analysts offering 1 year price forecasts for AKBA have a max estimate of 10.00 and a min estimate of 6.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in the CKD anemia market with Roxadustat (Evrenzo), an approved HIF-PH inhibitor.
Weight: 95
Direct competitor in the CKD anemia market with Daprodustat (Jesduvroq), an approved HIF-PH inhibitor.
Weight: 90
Co-developed Roxadustat with AstraZeneca, a key player in the HIF-PH inhibitor class, sharing a similar regulatory journey in the CKD anemia space.
Weight: 88
Historically dominant in the CKD anemia market with ESAs (Epogen, Aranesp) that HIF-PH inhibitors aim to displace; also has a strong nephrology presence through acquisitions.